Elizabeth Coulthard

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2403043/publications.pdf

Version: 2024-02-01

69 papers

2,133 citations

218677 26 h-index 254184 43 g-index

78 all docs

78 docs citations

78 times ranked 3973 citing authors

#	Article	IF	CITATIONS
1	Caffeine and attentional control: improved and impaired performance in healthy older adults and Parkinson's disease according to task demands. Psychopharmacology, 2022, 239, 605-619.	3.1	4
2	Assessment and Treatment of Nocturia in Neurological Disease in a Primary Care Setting: Systematic Review and Nominal Group Technique Consensus. European Urology Focus, 2022, 8, 33-41.	3.1	3
3	APOE Îμ4, Alzheimer's disease neuropathology and sleep disturbance, in individuals with and without dementia. Alzheimer's Research and Therapy, 2022, 14, 47.	6.2	12
4	The past, present, and future of sleep measurement in mild cognitive impairment and early dementiaâ€"towards a core outcome set: a scoping review. Sleep, 2022, 45, .	1.1	8
5	Mutationâ€related magnetizationâ€transfer, not axon density, drives white matter differences in premanifest Huntington disease: Evidence from in vivo ultraâ€strong gradient <scp>MRI</scp> . Human Brain Mapping, 2022, 43, 3439-3460.	3.6	5
6	Preliminary evidence that caffeine improves attention in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 64, 103924.	2.0	1
7	Pharmacological and nonâ€pharmacological interventions to enhance sleep in mild cognitive impairment and mild Alzheimer's disease: A systematic review. Journal of Sleep Research, 2021, 30, e13229.	3.2	49
8	Is disrupted sleep a risk factor for Alzheimer's disease? Evidence from a two-sample Mendelian randomization analysis. International Journal of Epidemiology, 2021, 50, 817-828.	1.9	31
9	Sleep and future cognitive decline. Brain, 2021, 144, 2568-2570.	7.6	2
10	Multi-compartment analysis of the complex gradient-echo signal quantifies myelin breakdown in premanifest Huntington's disease. Neurolmage: Clinical, 2021, 30, 102658.	2.7	6
11	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer's subjects?. Alzheimer's Research and Therapy, 2021, 13, 47.	6.2	32
12	Understanding the Impact of Urinary Incontinence in Persons with Dementia: Development of an Interdisciplinary Service Model. Advances in Urology, 2021, 2021, 1-6.	1.3	4
13	Sleep and the risk of cognitive impairment and dementia: further insights from the Caerphilly Prospective Study. BJPsych Open, 2021, 7, S49-S49.	0.7	0
14	#3122â€Is subjective cognitive decline (SCD) a better marker of susceptibility to functional cognitive disorder (FCD) than to neurodegeneration?: The caerphilly prospective study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, A4.1-A4.	1.9	0
15	Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 537-547.	10.2	55
16	E05â€Mutation-related apparent myelin, not axon density, drives white matter pathology in premanifest huntington's disease: evidence from in vivo ultra-strong gradient MRI. , 2021, , .		0
17	A passive and objective measure of recognition memory in Alzheimer's disease using Fastball memory assessment. Brain, 2021, 144, 2812-2825.	7.6	4
18	Metacognitive Performance on Memory and Visuospatial Tasks in Functional Cognitive Disorder. Brain Sciences, 2021, 11, 1368.	2.3	10

#	Article	IF	CITATIONS
19	Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2021, 20, 895-906.	10.2	26
20	Crossâ€sectional associations between sleep quality reports and core Alzheimer's disease biomarkers in cognitively unimpaired adults from the European Prevention of Alzheimer's Dementia Longitudinal Cohort Study (EPAD LCS). Alzheimer's and Dementia, 2021, 17, .	0.8	0
21	Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series. Molecular Psychiatry, 2020, 25, 3399-3412.	7.9	34
22	EEG microstate complexity for aiding early diagnosis of Alzheimer's disease. Scientific Reports, 2020, 10, 17627.	3.3	77
23	Teaching Neuroimages: COVID-19 associated acute disseminated encephalomyelitis with corpus callosal hemorrhage. Neurology, 2020, 96, 10.1212/WNL.00000000011001.	1.1	5
24	Drumming Motor Sequence Training Induces Apparent Myelin Remodelling in Huntington's Disease: A Longitudinal Diffusion MRI and Quantitative Magnetization Transfer Study. Journal of Huntington's Disease, 2020, 9, 303-320.	1.9	12
25	Mixed neuropathology in frontotemporal lobar degeneration. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 301-308.	1.7	2
26	Prospective memory in prodromal Alzheimer's disease: Real world relevance and correlations with cortical thickness and hippocampal subfield volumes. NeuroImage: Clinical, 2020, 26, 102226.	2.7	7
27	Napâ€mediated benefit to implicit information processing across age using an affective priming paradigm. Journal of Sleep Research, 2019, 28, e12728.	3.2	4
28	Neural correlates of altered insight in frontotemporal dementia: a systematic review. NeuroImage: Clinical, 2019, 24, 102066.	2.7	14
29	Novel Blood Biomarkers that Correlate with Cognitive Performance and Hippocampal Volumetry: Potential for Early Diagnosis of Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 67, 931-947.	2.6	18
30	Network substrates of cognitive impairment in Alzheimer's Disease. Clinical Neurophysiology, 2019, 130, 1581-1595.	1.5	25
31	Meaningful and Measurable Health Domains in Huntington's Disease: Large-Scale Validation of the Huntington's Disease Health-Related Quality of Life Questionnaire Across Severity Stages. Value in Health, 2019, 22, 712-720.	0.3	6
32	Levodopa does not affect expression of reinforcement learning in older adults. Scientific Reports, 2019, 9, 6349.	3.3	4
33	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: study protocol for a randomised controlled trial (ELAD study). Trials, 2019, 20, 191.	1.6	127
34	T2 Relaxometry and Diffusion Tensor Indices of the Hippocampus and Entorhinal Cortex Improve Sensitivity and Specificity of MRI to Detect Amnestic Mild Cognitive Impairment and Alzheimer's Disease Dementia. Journal of Magnetic Resonance Imaging, 2019, 49, 445-455.	3.4	30
35	Myelin Breakdown in Human Huntington's Disease: Multi-Modal Evidence from Diffusion MRI and Quantitative Magnetization Transfer. Neuroscience, 2019, 403, 79-92.	2.3	51
36	Functional Cognitive Disorder., 2019,,.		0

#	Article	IF	Citations
37	Incomplete Hippocampal Inversion and Its Relationship to Hippocampal Subfield Volumes and Aging. Journal of Neuroimaging, 2018, 28, 422-428.	2.0	8
38	Effects of Parkinson's disease and dopamine on digit span measures of working memory. Psychopharmacology, 2018, 235, 3443-3450.	3.1	16
39	A broader view of dementia: multiple co-pathologies are the norm. Brain, 2018, 141, 1894-1897.	7.6	25
40	Tools for testing decision-making capacity in dementia. Age and Ageing, 2018, 47, 778-784.	1.6	31
41	Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study. Lancet Neurology, The, 2017, 16, 701-711.	10.2	248
42	The impact of ageing reveals distinct roles for human dentate gyrus and CA3 in pattern separation and object recognition memory. Scientific Reports, 2017, 7, 14069.	3.3	48
43	Refining Alzheimer's disease diagnosis with MRI. Brain, 2017, 140, 524-526.	7.6	1
44	The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial. Journal of Alzheimer's Disease, 2017, 61, 803-814.	2.6	28
45	Magnetic Resonance Imaging to Detect Early Molecular and Cellular Changes in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2016, 8, 139.	3.4	31
46	Quantitative T2 mapping of white matter: applications for ageing and cognitive decline. Physics in Medicine and Biology, 2016, 61, 5587-5605.	3.0	29
47	Enhancing attention in neurodegenerative diseases: current therapies and future directions. Translational Neuroscience, 2016, 7, 98-109.	1.4	8
48	A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol. Trials, 2016, 17, 324.	1.6	6
49	Functional Cognitive Disorder: A Common Cause of Subjective Cognitive Symptoms. Journal of Alzheimer's Disease, 2015, 48, S19-S24.	2.6	30
50	Magnetic resonance scanning and image segmentation procedure at 3 T for volumetry of human hippocampal subfields. Biomedical Spectroscopy and Imaging, 2015, 4, 197-208.	1.2	7
51	Dopamine and Consolidation of Episodic Memory: Timing Is Everything. Journal of Cognitive Neuroscience, 2015, 27, 2035-2050.	2.3	21
52	A defect in the retromer accessory protein, SNX27, manifests by infantile myoclonic epilepsy and neurodegeneration. Neurogenetics, 2015, 16, 215-221.	1.4	44
53	Functional cognitive disorder: what is it and what to do about it?. Practical Neurology, 2015, 15, 436-444.	1.1	36
54	Paraneoplastic tumefactive demyelination with underlying combined germ cell cancer. Practical Neurology, 2015, 15, 451-455.	1.1	12

#	Article	IF	CITATIONS
55	Improved Executive Function and Callosal White Matter Microstructure after Rhythm Exercise in Huntington's Disease. Journal of Huntington's Disease, 2014, 3, 273-283.	1.9	46
56	Memory consolidation $\hat{a}\in$ "Mechanisms and opportunities for enhancement. Translational Neuroscience, 2013, 4, 448-457.	1.4	2
57	Distinct roles of dopamine and subthalamic nucleus in learning and probabilistic decision making. Brain, 2012, 135, 3721-3734.	7.6	73
58	Role of right posterior parietal cortex in maintaining attention to spatial locations over time. Brain, 2009, 132, 645-660.	7.6	206
59	Control over Conflict during Movement Preparation: Role of Posterior Parietal Cortex. Neuron, 2008, 58, 144-157.	8.1	70
60	Enantiomorphic normalization of focally lesioned brains. NeuroImage, 2008, 39, 1215-1226.	4.2	192
61	Bringing cognitive testing into the real world. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 363-363.	1.9	0
62	Alien limb following posterior cerebral artery stroke: Failure to recognize internally generated movements?. Movement Disorders, 2007, 22, 1498-1502.	3.9	25
63	The modular architecture of the neglect syndrome: Implications for action control in visual neglect. Neuropsychologia, 2007, 45, 1982-1984.	1.6	19
64	Hemispatial neglect, balance and eye-movement control. Current Opinion in Neurology, 2006, 19, 14-20.	3.6	37
65	Treatment of attention deficits in neurological disorders. Current Opinion in Neurology, 2006, 19, 613-618.	3.6	34
66	Proton magnetic resonance spectroscopy in frontotemporal dementia. Journal of Neurology, 2006, 253, 861-868.	3.6	35
67	Action control in visual neglect. Neuropsychologia, 2006, 44, 2717-2733.	1.6	48
68	Neuropharmacological modulation of cognitive deficits after brain damage. Current Opinion in Neurology, 2005, 18, 675-680.	3.6	37
69	Protocol for a scoping review of measurement of sleep in mild cognitive impairment and early dementia. AMRC Open Research, 0, 3, 13.	1.7	O